ÂÜÀòÂÒÂ×

With a career spanning over 25 years of international experience in the healthcare industry, Robert retired from Johnson and Johnson in 2018 as the Global Head of Johnson & Johnson Innovation, LLC. While at J&J, Robert was a member the R&D Management Committee (RDMC), the group chartered to oversee the allocation of the company’s ~$10B annual R&D budget. Under his leadership, the J&J Innovation brand and global platform was launched and became the #1 recognized cross-sector (pharm, med device and consumer) innovation leader with a portfolio encompassing over 400 individual investments, including a globally distributed suite of incubators (JLABS) hosting over 300 start-ups and collectively generating a risk-adjusted enterprise value of over $5B.

Prior to joining J&J, Robert was the founding Executive Director of the Koch Institute for Integrative Cancer Research at M.I.T. He was previously the CEO of Acretia Inc., and has also held founding and executive positions at ZYCOS Inc. and Pangaea Pharmaceuticals. He has served on the Board of diverse companies and not-for-profit organizations. He has in-depth experience in global organizational management, healthcare product development and fundraising. Robert holds both bachelor and doctoral degrees from the University of Texas System and was an Irvington Fellow in Structural Immunology at Harvard University.